1Russo CAt Licciardello M, La Spina M. Rituximab in children with idiopathic thrombocytopenie purpura: dose it really work? EurJ Pediatr, 2004 ; 163:569.
2Bengtson KL, Skinner MA, Ware RE. Successful use of anti-CD20 (Rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. JPediatr, 2003 ;143:670-3.
3Roganovic J. Rituximab treatment in refractory idiopathic thrombocytopenic purpura in children. Eur J Pediatr, 2005 ;164:334.
4Pusiol A, Cesaro S, Nocefino A, et al. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia. Eur J Pediatr, 2004 ; 163:305-307.
5Moschovi M, Trimis C4 Pergantou H, et al. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thromhocytopenic purpura. J Paediatr Child Health, 2005 ;41:384-386.
6Bay A, Oner AF, Uner A and Dogan M. Use of rituximab in chronic childhood immune thrombocytopenic purpura. Pediatrics international, 2006 ;48:514-516.
7Bennett CM, Rogers ZR, Kinnamon D, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006 ; 107:2639-2642.
8Franchini M. Zaffanello M, Veneri D and Lippi Giuseppe. Rituximab for thr treatment of childhood chronic idiopathic thrombocytopenic pmpura and hemophilia with inhibitors. Pediatr Blood Cancer, 2007 ;49:6-10.
9Gianni Bisogno. Persistent B-cell depletion after rituximab for thrombocytopenic purpura. Eur J Pediatr, 2007 ;166:85-86.
10Brouchov D, Gururangan S, Driscoll MC, Bussel J. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenie purpura. Blood, 2007 ;110:3526-3531.
3Rodeghiero F,Stasi R,Gernsheimer T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group[J].Blood,2009,113(11):2386.
